SB-207266 (also known as Piboserod or SB-207266) is a small molecule inhibitor used for the treatment of irritable bowel syndrome (IBS). In this article, we will explore the properties, uses, health benefits, potential effects, mechanism, safety, side effects, and dosing information of SB-207266.
Introduction: SB-207266 is a novel small molecule inhibitor that targets the 5-HT4 receptor, which plays a key role in regulating gastrointestinal motility. By modulating 5-HT4 receptor activity, SB-207266 has shown promise in preclinical studies as an IBS therapy.
Chemical name: The chemical name of SB-207266 (Piboserod or SB-207266) is (R)-(+)-trans-N-(3-chlorophenyl)-N'-[(cis-3-fluoro-1-azabicyclo[2.2.2]oct-3-yl)oxy]propane-1,2-diamine.
Molecular formula: The molecular formula of SB-207266 is C17H22ClFN3O.
Formula weight: The formula weight of SB-207266 is 339.83 g/mol.
CAS No: The CAS number for SB-207266 (Piboserod or SB-207266) is 152811-62-6.
Top ten keywords from Google and Synonyms:
Health benefits of SB-207266: As a potential IBS therapy, SB-207266 has the potential to provide significant health benefits to patients suffering from various forms of IBS. By modulating 5-HT4 receptor activity, this compound may be able to alleviate gastrointestinal symptoms and improve patient quality of life.
Potential effects: SB-207266 has been shown to have potent prokinetic activity in preclinical studies, with efficacy demonstrated against various forms of IBS, including IBS with constipation (IBS-C) and IBS with diarrhea (IBS-D). The compound has also shown promise in combination with other gastrointestinal therapies, such as laxatives and antidiarrheals.
Product mechanism: SB-207266 acts by selectively modulating the activity of the 5-HT4 receptor, which is involved in regulating gastrointestinal motility. By enhancing 5-HT4 receptor activity, the compound can increase colonic transit time, promote stool frequency, and reduce abdominal pain and discomfort.
Safety: As with any new drug candidate, the safety of SB-207266 is still being evaluated in preclinical and clinical studies. However, early results suggest that the compound is generally well-tolerated, with manageable toxicity profiles. Ongoing studies will continue to monitor the safety of this compound.
Side effects: As with all drugs, there is the potential for side effects when using SB-207266. Some potential side effects include headache, nausea, vomiting, and diarrhea. More serious side effects may occur in some patients, and these should be monitored closely by healthcare professionals.
Dosing information: The optimal dosing regimen for SB-207266 is still being determined in clinical trials. However, early studies suggest that the compound is most effective when administered orally once daily, with dosages ranging from 10-40 mg per day. Dosing should always be determined by a healthcare professional and based on the individual needs of the patient.
Conclusion: SB-207266 (Piboserod or SB-207266) represents a promising new IBS therapy that selectively modulates the 5-HT4 receptor to alleviate gastrointestinal symptoms and improve patient quality of life. While the compound is still in the early stages of development, preclinical studies suggest that it has potent prokinetic activity and manageable toxicity profiles. Ongoing clinical trials will help determine the optimal dose and safety profile of this compound, paving the way for its eventual use in IBS management.
